The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials
Abstract Background Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease‐2019 (COVID‐19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID‐19. Aims We aimed to per...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-02-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.562 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850152878506770432 |
|---|---|
| author | Chia Siang Kow Learn‐Han Lee Dinesh Sangarran Ramachandram Syed Shahzad Hasan Long Chiau Ming Hui Poh Goh |
| author_facet | Chia Siang Kow Learn‐Han Lee Dinesh Sangarran Ramachandram Syed Shahzad Hasan Long Chiau Ming Hui Poh Goh |
| author_sort | Chia Siang Kow |
| collection | DOAJ |
| description | Abstract Background Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease‐2019 (COVID‐19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID‐19. Aims We aimed to perform a meta‐analysis of randomized trials investigating the effect of colchicine in patients with COVID‐19. Materials & Methods We systematically searched electronic databases and clinical trial registries (up to October 17, 2021) for eligible studies. The outcomes of interest were all‐cause mortality and duration of hospital stay. Meta‐analysis with the random‐effects model was used to estimate the pooled odds ratio (OR) of mortality and 95% confidence interval (CI). The pooled standardized mean difference of duration of hospital stay with 95% CI between colchicine users and non‐colchicine users was estimated using Cohen's d index. Results The meta‐analyses revealed no significant difference in the odds of mortality (pooled OR = 0.76; 95% CI: 0.53–1.07), but a significant reduction in the duration of hospital stay with the use of colchicine (pooled standardized mean difference = −0.59; 95% CI: −1.06 to −0.13). Discussion and Conclusion The ability of colchicine to reduce the length of stay in hospitalized patients with COVID‐19 is consistent with its potential to prevent clinical deterioration via inhibition of NLRP3 inflammasome. Nevertheless, such beneficial effects of colchicine did not translate into mortality benefits in patients with COVID‐19. |
| format | Article |
| id | doaj-art-3b3eee45553e45f0984e4d158b06fd10 |
| institution | OA Journals |
| issn | 2050-4527 |
| language | English |
| publishDate | 2022-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-3b3eee45553e45f0984e4d158b06fd102025-08-20T02:25:51ZengWileyImmunity, Inflammation and Disease2050-45272022-02-0110225526410.1002/iid3.562The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trialsChia Siang Kow0Learn‐Han Lee1Dinesh Sangarran Ramachandram2Syed Shahzad Hasan3Long Chiau Ming4Hui Poh Goh5School of Postgraduate Studies International Medical University Kuala Lumpur MalaysiaNovel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences Monash University Malaysia Subang Jaya Selangor MalaysiaSchool of Pharmacy Monash University Malaysia Subang Jaya Selangor MalaysiaDepartment of Pharmacy University of Huddersfield Huddersfield UKPAP Rashidah Sa'adatul Bolkiah Institute of Health Sciences Universiti Brunei Darussalam Gadong Brunei DarussalamPAP Rashidah Sa'adatul Bolkiah Institute of Health Sciences Universiti Brunei Darussalam Gadong Brunei DarussalamAbstract Background Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease‐2019 (COVID‐19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID‐19. Aims We aimed to perform a meta‐analysis of randomized trials investigating the effect of colchicine in patients with COVID‐19. Materials & Methods We systematically searched electronic databases and clinical trial registries (up to October 17, 2021) for eligible studies. The outcomes of interest were all‐cause mortality and duration of hospital stay. Meta‐analysis with the random‐effects model was used to estimate the pooled odds ratio (OR) of mortality and 95% confidence interval (CI). The pooled standardized mean difference of duration of hospital stay with 95% CI between colchicine users and non‐colchicine users was estimated using Cohen's d index. Results The meta‐analyses revealed no significant difference in the odds of mortality (pooled OR = 0.76; 95% CI: 0.53–1.07), but a significant reduction in the duration of hospital stay with the use of colchicine (pooled standardized mean difference = −0.59; 95% CI: −1.06 to −0.13). Discussion and Conclusion The ability of colchicine to reduce the length of stay in hospitalized patients with COVID‐19 is consistent with its potential to prevent clinical deterioration via inhibition of NLRP3 inflammasome. Nevertheless, such beneficial effects of colchicine did not translate into mortality benefits in patients with COVID‐19.https://doi.org/10.1002/iid3.562Coronavirus diseaseinflammasomeNLRP3 inhibitorSARS-CoV-2systematic review |
| spellingShingle | Chia Siang Kow Learn‐Han Lee Dinesh Sangarran Ramachandram Syed Shahzad Hasan Long Chiau Ming Hui Poh Goh The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials Immunity, Inflammation and Disease Coronavirus disease inflammasome NLRP3 inhibitor SARS-CoV-2 systematic review |
| title | The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials |
| title_full | The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials |
| title_fullStr | The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials |
| title_full_unstemmed | The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials |
| title_short | The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials |
| title_sort | effect of colchicine on mortality outcome and duration of hospital stay in patients with covid 19 a meta analysis of randomized trials |
| topic | Coronavirus disease inflammasome NLRP3 inhibitor SARS-CoV-2 systematic review |
| url | https://doi.org/10.1002/iid3.562 |
| work_keys_str_mv | AT chiasiangkow theeffectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT learnhanlee theeffectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT dineshsangarranramachandram theeffectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT syedshahzadhasan theeffectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT longchiauming theeffectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT huipohgoh theeffectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT chiasiangkow effectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT learnhanlee effectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT dineshsangarranramachandram effectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT syedshahzadhasan effectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT longchiauming effectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials AT huipohgoh effectofcolchicineonmortalityoutcomeanddurationofhospitalstayinpatientswithcovid19ametaanalysisofrandomizedtrials |